Associate Professor Michael Hill
Contact information
Michael Hill
DPhil
Laboratory Scientific Director
Associate Professor Mike Hill joined the Clinical Trial Service Unit & Epidemiological Studies Unit (CTSU) in 2009 and is the Laboratory Scientific Director of the Wolfson Laboratories. He has a background in population-based studies and functional studies associated with respiratory and cardiovascular disease.
He manages a team of 40 research and technical staff and is responsible for senior strategic oversight of all aspects of laboratory research within Oxford Population Health. Mike works closely with the department's principal investigators, providing central laboratory support for their clinical trials and observational studies ensuring the scientific integrity of the laboratory work.
Research interests include investigating new biochemical markers and validating analytical methods suitable for large-scale research. Wolfson Laboratories are a UKAS accredited testing laboratory (ISO 17025:2017 No. 2799) with extensive computer automation and a particular expertise in developing reliable high-throughput methods of analysis in clinical chemistry and protein biomarkers.
Mike gained his DPhil at the University of Oxford in 1992 and continued his post-doctoral studies at the Nuffield Department of Clinical Medicine, Oxford and The Wellcome Trust Centre for Human Genetics, Oxford. In 1998, he joined the Division of Medicine at University College London where he led a research group.
Recent publications
-
Type 2 diabetes and cause-specific mortality in Mexico City: a Mendelian randomisation analysis
EMBERSON J. et al, (2025), The Lancet Regional Health - Americas
-
Comparative studies of 2168 plasma proteins measured by two affinity-based platforms in 4000 Chinese adults.
Wang B. et al, (2025), Nat Commun, 16
-
Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease.
EMPA-KIDNEY Collaborative Group None. et al, (2025), N Engl J Med, 392, 777 - 787
-
Risk prediction of ischemic heart disease using plasma proteomics, conventional risk factors and polygenic scores in Chinese and European adults.
Mazidi M. et al, (2024), Eur J Epidemiol, 39, 1229 - 1240
-
Blood Pressure, eGFR, and Kidney Mortality in Mexico: A Prospective Study of 150,000 Adults
Zhu D. et al, (2024), Journal of the American Society of Nephrology, 35